144 related articles for article (PubMed ID: 30443968)
1. Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Wu Y; Qu X; Wang Y; Xia J; Gu Y; Qian Q; Hong Y
Andrologia; 2019 Mar; 51(2):e13198. PubMed ID: 30443968
[TBL] [Abstract][Full Text] [Related]
2. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Gallina A; Bianchi M; Gandaglia G; Cucchiara V; Suardi N; Montorsi F; Briganti A
Eur Urol; 2015 Nov; 68(5):750-3. PubMed ID: 25700565
[TBL] [Abstract][Full Text] [Related]
3. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
5. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
Wang X; Wang X; Liu T; He Q; Wang Y; Zhang X
PLoS One; 2014; 9(3):e91327. PubMed ID: 24618671
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.
Tian D; Wang XY; Zong HT; Zhang Y
Clin Interv Aging; 2017; 12():405-412. PubMed ID: 28260869
[TBL] [Abstract][Full Text] [Related]
9. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
10. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.
Zhang L; Wu B; Zha Z; Zhao H; Jiang Y; Yuan J
World J Surg Oncol; 2018 Jul; 16(1):124. PubMed ID: 29970100
[TBL] [Abstract][Full Text] [Related]
11. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies.
Scosyrev E; Tobis S; Donsky H; Wu G; Joseph J; Rashid H; Messing E
BJU Int; 2013 Mar; 111(3 Pt B):E71-7. PubMed ID: 23017100
[TBL] [Abstract][Full Text] [Related]
12. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.
Qiu S; Tang Z; Deng L; Liu L; Han P; Yang L; Wei Q
Sci Rep; 2016 Sep; 6():32853. PubMed ID: 27611008
[TBL] [Abstract][Full Text] [Related]
14. Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma.
Loeb S; Schlomm T; Stattin P
Eur Urol; 2015 Nov; 68(5):754-5. PubMed ID: 26238432
[No Abstract] [Full Text] [Related]
15. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
[TBL] [Abstract][Full Text] [Related]
16. Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy.
Michl U; Molfenter F; Graefen M; Tennstedt P; Ahyai S; Beyer B; Budäus L; Haese A; Heinzer H; Oh SJ; Salomon G; Schlomm T; Steuber T; Thederan I; Huland H; Tilki D
J Urol; 2015 Feb; 193(2):479-83. PubMed ID: 25196656
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
Fode M; Østergren PB; Jensen CFS; Jakobsen H; Sønksen J
Scand J Urol; 2018 Apr; 52(2):108-110. PubMed ID: 29057723
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis.
Hua Q; Zhu Y; Liu H; Ye X
Int Urol Nephrol; 2016 Sep; 48(9):1437-43. PubMed ID: 27170341
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
